DiaMedica Therapeutics (DMAC)
(Real Time Quote from BATS)
$3.49 USD
+0.04 (1.16%)
Updated Aug 2, 2024 02:44 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
DMAC 3.49 +0.04(1.16%)
Will DMAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DMAC
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
Other News for DMAC
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
Craig-Hallum Releases a Buy Rating on Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia